Malaysia Advances Genomics-Driven Healthcare at Next Generation Genomics Congress Asia 2026

Shah Alam, Malaysia – 31 March 2026 – Malaysia has reinforced its commitment to transforming healthcare through genomics at the Next Generation Genomics Congress Asia 2026, held at the National Institutes of Health (NIH), Selangor.

The two-day congress, co-hosted with the Institute for Medical Research (IMR), brought together leading experts across academia, healthcare, and industry to explore the latest advancements in next-generation sequencing (NGS), multi-omics, and AI-driven molecular diagnostics.

Malaysia Positions Genomics at the Core of Future Healthcare

During the opening session, Deputy Health Minister Datuk Hanifah Hajar Taib emphasised that Malaysia is actively integrating genomics into its national healthcare strategy—shifting from reactive treatment to predictive and personalised care.

“Malaysia is committed to leveraging genomics to strengthen healthcare delivery—moving towards early detection, precision treatment, and better patient outcomes. Our goal is to ensure these advanced technologies remain accessible and beneficial to all Malaysians.”

The initiative is anchored by MyGENOM, Malaysia’s national population genomics programme, which aims to build a comprehensive genomic database to support:

• Early disease risk prediction

• Precision oncology and pharmacogenomics

• Rare disease diagnosis

• Population health management

This national direction underscores Malaysia’s ambition to become a regional leader in precision medicine.

AGTC Genomics Showcases Real-World Clinical Implementation

Representing industry leadership, Prof. Dr. Chee-Onn Leong, Founder & CEO of AGTC Genomics, delivered a plenary presentation titled:

“From Tissue to Blood: How Liquid Biopsy is Transforming Precision Oncology in Asia”

His presentation highlighted how advances in NGS have enabled highly sensitive detection of circulating tumor DNA (ctDNA), paving the way for non-invasive, real-time cancer management.

“We are witnessing a fundamental shift in oncology—from static tissue-based testing to dynamic, blood-based monitoring. Liquid biopsy enables clinicians to make faster, more precise decisions, while reducing the burden on patients.”

Prof. Leong further emphasised the importance of translating genomics into routine clinical care:

“The true value of genomics lies not in data generation, but in clinical actionability. At AGTC Genomics, our focus is to bring these technologies from the lab to the bedside—making precision medicine accessible, affordable, and impactful.”

From Research to Clinical Practice

The congress highlighted the growing convergence of technologies shaping the future of healthcare, including:

• Integration of NGS, PCR, CRISPR, and spatial omics

• Use of AI for variant interpretation and clinical decision support

• Expansion of genomics into infectious diseases, oncology, and rare diseases

• Increasing need for standardisation, accreditation, and clinical adoption

These developments reflect a broader shift across Asia—where genomics is rapidly transitioning from research into real-world healthcare implementation.

Strengthening Malaysia as a Regional Genomics Hub

The event also reinforced Malaysia’s role as an emerging hub for genomics innovation, driven by strong collaboration between:

• Government agencies

• Healthcare institutions

• Academic partners

• Industry leaders

AGTC Genomics continues to play a pivotal role in this ecosystem by providing:

• Locally delivered, CAP and ISO-accredited genomic testing

• Advanced sequencing platforms across multiple technologies

• Affordable precision medicine solutions tailored for Asia

Driving the Future of Precision Medicine

The Next Generation Genomics Congress Asia 2026 marks a significant milestone in aligning national policy, scientific innovation, and clinical application.

With strong government support and active industry participation, Malaysia is well-positioned to lead the next phase of genomics-driven healthcare transformation in Asia.

“From early detection to treatment monitoring, genomics is no longer the future—it is already transforming how we care for patients today,” added Prof. Leong.

---

About AGTC Genomics

AGTC Genomics is a leading precision medicine and genomics company in Southeast Asia, operating ISO 15189, ISO 17025 and CAP-accredited laboratories. The company provides comprehensive genomic solutions across oncology, rare diseases, pharmacogenomics, and population health—enabling clinicians and researchers to deliver more precise, personalised, and effective care.